Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.
Yajima H, Anraku Y, Kaku Y, Kimura KT, Plianchaisuk A, Okumura K, Nakada-Nakura Y, Atarashi Y, Hemmi T, Kuroda D, Takahashi Y, Kita S, Sasaki J, Sumita H; Genotype to Phenotype Japan (G2P-Japan) Consortium; Ito J, Maenaka K, Sato K, Hashiguchi T. Yajima H, et al. Among authors: atarashi y. Nat Commun. 2024 Oct 7;15(1):8574. doi: 10.1038/s41467-024-52808-2. Nat Commun. 2024. PMID: 39375326 Free PMC article.
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer.
Sakaeda K, Kurose K, Matsumura Y, Muto S, Fukuda M, Sugasaki N, Fukuda M, Takemoto S, Taniguchi H, Masuda T, Shimizu K, Kataoka Y, Irino Y, Sakai Y, Atarashi Y, Yanagida M, Hattori N, Mukae H, Nakata M, Kanda E, Oga T, Suzuki H, Oka M. Sakaeda K, et al. Among authors: atarashi y. Cancer Treat Res Commun. 2024;40:100830. doi: 10.1016/j.ctarc.2024.100830. Epub 2024 Jun 28. Cancer Treat Res Commun. 2024. PMID: 38964205 Free article.
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Kurose K, et al. Among authors: atarashi y. Adv Clin Chem. 2023;112:155-204. doi: 10.1016/bs.acc.2022.09.004. Epub 2022 Nov 17. Adv Clin Chem. 2023. PMID: 36642483 Review.
A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer.
Sakai Y, Kurose K, Sakaeda K, Abo H, Atarashi Y, Ide N, Sato T, Kanda E, Fukuda M, Oga T, Noda K, Oka M. Sakai Y, et al. Among authors: atarashi y. Clin Chim Acta. 2021 Aug;519:51-59. doi: 10.1016/j.cca.2021.04.008. Epub 2021 Apr 15. Clin Chim Acta. 2021. PMID: 33865813 Free article.
Dietary supplement implicated in fulminant hepatic failure in a well-controlled Wilson disease patient.
Kawai K, Atarashi Y, Takahara T, Kudo H, Tajiri K, Tokimitsu Y, Nakayama Y, Hirano K, Yata Y, Minemura M, Yasumura S, Onishi Y, Tsukada K, Tsuneyama K, Takano Y, Sugiyama T. Kawai K, et al. Among authors: atarashi y. Clin J Gastroenterol. 2009 Apr;2(2):119-124. doi: 10.1007/s12328-008-0056-6. Epub 2009 Jan 22. Clin J Gastroenterol. 2009. PMID: 26192177
18 results